Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Women's Health Rheumatology Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Clinical Trial ● Currently Recruiting NCT07787299

Wearable for Assessing Tremor and Continuous Health in Parkinson’s Disease and Essential Tremor

Wearable for Assessing Tremor and Continuous Health in Parkinson’s Disease and Essential Tremor — Recruiting • Neurology • NCT07787299.

📅 09 Oct 2026 ⏱ 2 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
NCT ID
NCT07787299
Sponsor
Heriot-Watt University
Start
2026-11-01
ClinicaliQ Trial Snapshot
  • Wearable for Assessing Tremor and Continuous Health in Parkinson’s Disease and Essential Tremor — Recruiting • Neurology • NCT07787299.
  • What is being tested: Non-invasive wearable sensors are being evaluated to measure tremor and upper-limb movement patterns in adults with Parkinson's disease or essential tremor, with monitoring periods ranging from 3 to 21 days in both clinic and home settings.
  • Patient eligibility overview: The study recruits adults diagnosed with either Parkinson's disease or essential tremor who are capable of attending an initial clinic visit and subsequently wearing the sensors during follow-up periods.
Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

This prospective observational study will examine tremor and upper-limb movement in adults with Parkinson's disease or essential tremor using non-invasive wearable sensors. Participants will attend one clinic visit and may then wear sensors at home for 3, 7, or 21 days. Clinic assessments will be scheduled around participants' usual medication times; the study will not change or delay treatment. Sensor data will be analysed offline for research and will not be used to make clinical decisions.

Eligibility Snapshot
  • : 1. Aged 18 years or older. 2. Clinical diagnosis of idiopathic Parkinson's disease (Hoehn and Yahr stage I-III) or essential tremor. 3. Motor or tremor symptoms confirmed on clinical assessment. 4. Able to walk at least 4 metres independently, with or without a walking aid. 5. Able to provide written informed consent and comply with study procedures. 6. Willing and able to wear the study sensors in clinic and, where applicable, at home. 7. Able to understand study information and complete study materials in English.

Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Clinical Brief
Smart beds and motion sensors – is this the future of dementia care?
Neurology · BBC Health · 20 Sep 2026
Key takeaways for clinical practice: Smart home technology including motion sensors, bed monitors, and wearable devices (socks) can enable remote monitoring of…
View brief →
Guideline
Software with artificial intelligence (AI)-derived algorithms to help interpret electroencephalograms (EEGs) for suspected epilepsy: early-use assessment
Neurology · 01 Oct 2026
AI-assisted EEG interpretation software can support clinicians in identifying abnormalities suggestive of epilepsy, but should complement rather than replace expert clinical review—use…
View guideline →
Guideline
Motor Neurone Disease: Assessment and Management (NICE NG42)
Neurology · 27 Mar 2026
Refer suspected MND urgently to a specialist neurology centre for diagnosis confirmation by an MND-experienced neurologist using clinical examination, EMG/NCS, imaging, and…
View guideline →
Guideline
Mirdametinib for treating symptomatic and inoperable plexiform neurofibromas associated with neurofibromatosis type 1 in people 2 to 17 years
Neurology · 16 Sep 2026
Mirdametinib is indicated for symptomatic and inoperable plexiform neurofibromas in children aged 2-17 years with neurofibromatosis type 1 (NF1); confirm diagnosis and…
View guideline →
Clinical Brief
AI may speed up search for drugs to treat brain conditions
Neurology · BBC Health · 22 May 2026
AI tools are being developed to accelerate drug discovery for neurological conditions including motor neurone disease, potentially reducing development timelines This approach…
View brief →
Clinical Brief
Anaemia and the new dementia link
Neurology · BBC Health · 07 May 2026
Key Takeaways for Clinical Practice Anaemia has been identified as a newly recognised risk factor for dementia, suggesting haemoglobin levels should be…
View brief →